What is HC Wainwright’s Forecast for Geron FY2027 Earnings?

Geron Corporation (NASDAQ:GERN) – Equities research analysts at HC Wainwright lowered their FY2027 earnings estimates for shares of Geron in a research report issued to clients and investors on Monday, July 13th. HC Wainwright analyst E. Bodnar now forecasts that the biopharmaceutical company will earn $0.04 per share for the year, down from their previous forecast of $0.05. The consensus estimate for Geron’s current full-year earnings is ($0.02) per share.

Geron (NASDAQ:GERN) last posted its quarterly earnings results on Wednesday, May 6th. The biopharmaceutical company reported ($0.01) earnings per share for the quarter, topping the consensus estimate of ($0.03) by $0.02. Geron had a negative net margin of 35.48% and a negative return on equity of 23.31%. The firm had revenue of $51.84 million for the quarter, compared to the consensus estimate of $50.59 million.

Separately, Weiss Ratings upgraded shares of Geron from a “sell (e+)” rating to a “sell (d-)” rating in a report on Thursday, July 9th. Two equities research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Hold” and a consensus price target of $4.00.

Geron Stock Down 2.8%

Shares of NASDAQ GERN opened at $1.38 on Wednesday. Geron has a 1 year low of $1.04 and a 1 year high of $2.01. The company has a debt-to-equity ratio of 0.52, a current ratio of 6.78 and a quick ratio of 4.96. The company has a market capitalization of $885.30 million, a P/E ratio of -12.55 and a beta of 0.60. The company has a 50 day simple moving average of $1.30 and a 200-day simple moving average of $1.45.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in GERN. Hennion & Walsh Asset Management Inc. raised its position in shares of Geron by 152.4% during the 2nd quarter. Hennion & Walsh Asset Management Inc. now owns 1,000,910 shares of the biopharmaceutical company’s stock worth $1,281,000 after acquiring an additional 604,278 shares in the last quarter. Foresight Capital Management Advisors Inc. purchased a new position in Geron during the 2nd quarter worth $80,000. Bank of America Corp DE grew its holdings in shares of Geron by 68.9% during the first quarter. Bank of America Corp DE now owns 4,556,278 shares of the biopharmaceutical company’s stock worth $6,789,000 after buying an additional 1,858,268 shares during the last quarter. Janus Henderson Group PLC grew its stake in shares of Geron by 826.7% in the 1st quarter. Janus Henderson Group PLC now owns 2,218,196 shares of the biopharmaceutical company’s stock valued at $3,304,000 after purchasing an additional 1,978,839 shares during the last quarter. Finally, Amundi increased its holdings in shares of Geron by 365.7% in the first quarter. Amundi now owns 132,367 shares of the biopharmaceutical company’s stock valued at $197,000 after purchasing an additional 103,944 shares during the period. Hedge funds and other institutional investors own 73.71% of the company’s stock.

About Geron

Geron Corporation (NASDAQ: GERN) is a clinical-stage biotechnology company dedicated to developing and commercializing novel treatments that target telomerase, an enzyme critical to cancer cell immortality. The company’s research is focused on hematologic malignancies and solid tumors, with a pipeline designed to address diseases that have historically had limited therapeutic options.

The lead product candidate, imetelstat, is a first-in-class telomerase inhibitor currently in Phase II and Phase III clinical trials for myelofibrosis and myelodysplastic syndromes.